Thermo Fisher Scientific Total Liabilities & Equity increased by 7.1% to $110.34B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 13.4%, from $97.32B to $110.34B. Over 5 years (FY 2020 to FY 2025), Total Liabilities & Equity shows an upward trend with a 9.8% CAGR.
An increase typically reflects overall balance sheet growth or expansion of the company's asset base, while a decrease may indicate divestitures or debt repayment.
This represents the sum of all claims against a company's assets, combining obligations to external creditors and the re...
This is a standard accounting identity used across all industries to verify that assets equal the sum of liabilities and equity.
total_liabilities_and_equity| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $67.70B | $73.60B | $95.12B | $92.75B | $90.58B | $90.54B | $97.15B | $94.66B | $94.11B | $97.06B | $98.73B | $97.10B | $98.50B | $100.36B | $97.32B | $99.04B | $101.23B | $103.02B | $110.34B |
| QoQ Change | — | +8.7% | +29.2% | -2.5% | -2.3% | -0.0% | +7.3% | -2.6% | -0.6% | +3.1% | +1.7% | -1.7% | +1.4% | +1.9% | -3.0% | +1.8% | +2.2% | +1.8% | +7.1% |
| YoY Change | — | — | — | — | +33.8% | +23.0% | +2.1% | +2.1% | +3.9% | +7.2% | +1.6% | +2.6% | +4.7% | +3.4% | -1.4% | +2.0% | +2.8% | +2.6% | +13.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.